Age-stratified analysis of adverse event signals for blinatumomab: a disproportionality analysis using the FDA Adverse Event Reporting System
Abstract
Background: Blinatumomab used to treat acute B lymphoblastic leukemia, while the actual safety data for it in different age groups is limited. Method: FAERS data were interrogated with ROR, PRR, BCPNN, and MGPS to identify significant safety signals. Subgroup analysis by age was performed to explore differences. The age groups were divided into minors (
Fields of Study & Subjects
Pharmacovigilance and Adverse Drug Reactions
Acute Lymphoblastic Leukemia research
Pharmaceutical studies and practices
Publication details
- Publication date
- 28 January 2026
- Document type
- Preprint